BHC Stock Overview
Operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bausch Health Companies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.45 |
| 52 Week High | US$9.85 |
| 52 Week Low | US$3.96 |
| Beta | 0.34 |
| 1 Month Change | -13.93% |
| 3 Month Change | -39.12% |
| 1 Year Change | -30.03% |
| 3 Year Change | -54.91% |
| 5 Year Change | -75.92% |
| Change since IPO | 790.00% |
Recent News & Updates
Recent updates
Refinancing And New Product Launches Will Unlock Future Possibilities
Strategic initiatives in product launches and pipeline advancements suggest potential revenue growth by meeting unmet medical needs.Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)
Feb 20Revenues Working Against Bausch Health Companies Inc.'s (NYSE:BHC) Share Price
Feb 18
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
Dec 03There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise
Oct 10Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Sep 19Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%
Aug 062 Red Alerts On Bausch Health Companies
Jul 25The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
May 21Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
May 07Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Shareholder Returns
| BHC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.7% | -1.7% | -2.7% |
| 1Y | -30.0% | -11.6% | 9.0% |
Return vs Industry: BHC underperformed the US Pharmaceuticals industry which returned -12.1% over the past year.
Return vs Market: BHC underperformed the US Market which returned 10.5% over the past year.
Price Volatility
| BHC volatility | |
|---|---|
| BHC Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 11.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: BHC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BHC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20,700 | Tom Appio | www.bauschhealth.com |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products.
Bausch Health Companies Inc. Fundamentals Summary
| BHC fundamental statistics | |
|---|---|
| Market cap | US$1.66b |
| Earnings (TTM) | -US$40.00m |
| Revenue (TTM) | US$9.73b |
Is BHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHC income statement (TTM) | |
|---|---|
| Revenue | US$9.73b |
| Cost of Revenue | US$2.84b |
| Gross Profit | US$6.89b |
| Other Expenses | US$6.93b |
| Earnings | -US$40.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 70.78% |
| Net Profit Margin | -0.41% |
| Debt/Equity Ratio | -8,962.5% |
How did BHC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 21:06 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bausch Health Companies Inc. is covered by 39 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Tsao | Barclays |
| Ardalan Arfaei | BMO Capital Markets Equity Research |
| Robert Hazlett | BMO Capital Markets U.S. (Historical) |